Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Pain of Non-Malignant Origin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Alvimopan (Primary)
- Indications Constipation
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 31 Oct 2012 New source identified and integrated (European Clinical Trials Database record: EudraCT2004-001182-18).
- 05 Nov 2010 New trial record.